Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers

Abstract

Aim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars.

Methods: Analysis of an administrative database for prescription in a rheumatology division. Biosimilars for adalimumab and etanercept were available in 2019. Blinded costs and prescription data were not shared with prescribing physicians until 2021. The rate of prescription, persistence of therapy after switching, and reduction of cost were analyzed from 2019 to 2022. A new etanercept biosimilar was prioritized in 2022, and a new switching wave from biosimilar to biosimilar etanercept was implemented.

Results: Overall switching from 2019 to 2022 comprised 132/135 (97.8%) of patients. The rate of switching increased from 13.3% to 34%, 79%, and 95.5% of patients on reference products during 2019, 2020, 2021, and 2022, respectively. In 2022, after sharing information, the switch comprised 55/135 (40.7%) of overall switching. The rate of persistence on therapy after switching was 86.8% for etanercept and 79.7 for adalimumab. During 2023, a rate of 76.6% switching etanercept reference-biosimilar-biosimilar was achieved. The reduction in the overall biologic budget in 2021 was 19.2% and 29.0% for the patient-year cost.

Conclusions: Information to prescribers may improve switching policies. Persistence on biosimilar medications after switching is as high as previously reported.

Keywords

Biologics / biosimilars / interchangeability / switching / cost

References

[1] Koopman WJ. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 2008; 58: S75-8.

[2] Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! BioDrugs. 2020; 34: 159-70.

[3] Widdifield J, Bernatsky S, Paterson JM, Tomlinson G, Tu K, Kuriya B, et al. Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada. Arthritis Care Res (Hoboken). 2015; 67: 1047-53.

[4] Guidelines on evaluation of biosimilars. Replacement of Annex 2 of WHO Technical Report Series, No. 977 [Internet]. World Health Organization; c2022 [cited 2024 Apr 12]. Available from: https://cdn.who.int/media/docs/default-source/biologicals/annex-3---who-guidelines-on-evaluation-of-biosimilars---sj-ik-5-may-2022.pdf?sfvrsn=9b2fa6d2_1&download=true

[5] Biosimilars in the EU: information guide for healthcare professionals 2019 [Internet]. European Medicines Agency; © 2019 [cited 2024 Apr 12]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

[6] Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. European Medicines Agency; © 2023 [cited 2024 Apr 12]. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf

[7] Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, et al. Capturing the holistic value of biosimilars in Europe-part 1: a historical perspective. Expert Rev Pharmacoecon Outcomes Res. 2024; 24: 237-50.

[8] Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024; 12: 1263472.

[9] Moorkens E, Lacosta TB, Dawoud D, Inotai A, Janodia M, Tan CJ, et al. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value Health. 2023; 26: 1137-44.

[10] Wu Q, Wang Z, Wang X, Yu H, Sun J. Patients’ Perceptions of Biosimilars: A Systematic Review. BioDrugs. 2023; 37: 829-41.

[11] Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, et al. Leveraging the holistic benefits of biosimilars in Europe-part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert Rev Pharmacoecon Outcomes Res. 2024; 24: 509-19.

[12] Tano M, Paubel P, Ribault M, Degrassat-Théas A. What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France. Appl Health Econ Health Policy. 2023; 21: 799-811.

[13] Fernández MG, Villamañán E, Jiménez-Nácher I, Moreno F, Plasencia C, Gayá F, et al. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. Reumatol Clin (Engl Ed). 2021; 17: 335-42.

[14] Gonzalez Franco RM, Gomez Gomez D, Valero Dominguez M. Introducción de biosimilares anti-TNF e impacto económico en un hospital de tercer nivel. Rev OFIL·ILAPHAR. 2023; 33: 21. Spanish.

[15] Müller-Ladner U, Dignass A, Gaffney K, Jadon D, Matucci-Cerinic M, Lobaton T, et al. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease. BioDrugs. 2023; 37: 873-89.